118 related articles for article (PubMed ID: 3129611)
1. Bone lead in dialysis patients.
Van de Vyver FL; D'Haese PC; Visser WJ; Elseviers MM; Knippenberg LJ; Lamberts LV; Wedeen RP; De Broe ME
Kidney Int; 1988 Feb; 33(2):601-7. PubMed ID: 3129611
[TBL] [Abstract][Full Text] [Related]
2. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients.
D'Haese PC; Couttenye MM; Lamberts LV; Elseviers MM; Goodman WG; Schrooten I; Cabrera WE; De Broe ME
Clin Chem; 1999 Sep; 45(9):1548-56. PubMed ID: 10471660
[TBL] [Abstract][Full Text] [Related]
3. Bone lead, hypertension, and lead nephropathy.
Wedeen RP
Environ Health Perspect; 1988 Jun; 78():57-60. PubMed ID: 3203647
[TBL] [Abstract][Full Text] [Related]
4. Aluminium in bone from patients with renal failure.
Parsons V; Davies C; Goode C; Ogg C; Siddiqui J
Br Med J; 1971 Oct; 4(5782):273-5. PubMed ID: 5123910
[TBL] [Abstract][Full Text] [Related]
5. Aluminum deposition in the bone of patients with chronic renal failure--detection of aluminum accumulation without signs of aluminum toxicity in bone using acid solochrome azurine.
Rüster M; Abendroth K; Lehmann G; Stein G
Clin Nephrol; 2002 Oct; 58(4):305-12. PubMed ID: 12400847
[TBL] [Abstract][Full Text] [Related]
6. Serum aluminium concentration and aluminium deposits in bone in patients receiving haemodialysis.
Charhon SA; Chavassieux PM; Meunier PJ; Accominotti M
Br Med J (Clin Res Ed); 1985 Jun; 290(6482):1613-4. PubMed ID: 3924189
[TBL] [Abstract][Full Text] [Related]
7. [Effect of strontium on bone metabolism in hemodialysis patients].
Gerstenfeld S; Hinojosa L; Serrano Arias M; Menéndez Rodríguez P; Fernández Martín JL; Marchante JM; García Alonso JI; Sanz-Medel A; Cannata Andía JB
Nefrologia; 2003; 23 Suppl 2():52-6. PubMed ID: 12778855
[TBL] [Abstract][Full Text] [Related]
8. Elevated bone aluminum content in dialysis patients without osteomalacia.
McCarthy JT; Kurtz SB; McCall JT
Mayo Clin Proc; 1985 May; 60(5):315-20. PubMed ID: 3990380
[TBL] [Abstract][Full Text] [Related]
9. Mineral content of iliac crest bone in patients with chronic renal failure.
Kaye M
Clin Nephrol; 1973; 1(6):347-50. PubMed ID: 4786574
[No Abstract] [Full Text] [Related]
10. A comparative study of bone biopsies from the iliac crest, the tibial bone, and the lumbar spine.
Hiller RG; Patecki M; Neunaber C; Reifenrath J; Kielstein JT; Kielstein H
BMC Nephrol; 2017 Apr; 18(1):134. PubMed ID: 28407760
[TBL] [Abstract][Full Text] [Related]
11. [Aluminum poisoning in renal dialysis patients: bone histology. Value of quantitative bone biopsy].
Charhon SA; Chapuy MC; Traeger J; Meunier PJ
Presse Med; 1984 Jun; 13(23):1431-4. PubMed ID: 6233588
[TBL] [Abstract][Full Text] [Related]
12. Relationship between hair, serum and bone aluminium in hemodialyzed patients.
Chappuis P; de Vernejoul MC; Paolaggi F; Rousselet F
Clin Chim Acta; 1989 Feb; 179(3):271-8. PubMed ID: 2714000
[TBL] [Abstract][Full Text] [Related]
13. Reducing bone lead content by chelation treatment in chronic lead poisoning: an in vivo X-ray fluorescence and bone biopsy study.
Batuman V; Wedeen RP; Bogden JD; Balestra DJ; Jones K; Schidlovsky G
Environ Res; 1989 Feb; 48(1):70-5. PubMed ID: 2492468
[TBL] [Abstract][Full Text] [Related]
14. Renal osteodystrophy in Ramathibodi Hospital: histomorphometry and clinical correlation.
Changsirikulchai S; Domrongkitchaiporn S; Sirikulchayanonta V; Ongphiphadhanakul B; Kunkitti N; Stitchantrakul W; Radienahamed P
J Med Assoc Thai; 2000 Oct; 83(10):1223-32. PubMed ID: 11143489
[TBL] [Abstract][Full Text] [Related]
15. Chronic lead nephropathy in Queensland: alternative methods of diagnosis.
Craswell PW; Price J; Boyle PD; Heazlewood VJ; Baddeley H; Lloyd HM; Thomas BJ; Thomas BW; Williams GM
Aust N Z J Med; 1986 Feb; 16(1):11-9. PubMed ID: 3085647
[TBL] [Abstract][Full Text] [Related]
16. 25-hydroxyvitamin D levels and bone histomorphometry in hemodialysis renal osteodystrophy.
Coen G; Mantella D; Manni M; Balducci A; Nofroni I; Sardella D; Ballanti P; Bonucci E
Kidney Int; 2005 Oct; 68(4):1840-8. PubMed ID: 16164662
[TBL] [Abstract][Full Text] [Related]
17. [Aluminum in renal osteodystrophy].
Zhu P; Wang GY; Yu YF; Zhu P
Zhonghua Nei Ke Za Zhi; 1993 Mar; 32(3):176-8. PubMed ID: 8222983
[TBL] [Abstract][Full Text] [Related]
18. Partial body calcium measurements on patients with renal failure.
Harrison JE; McNeill KG; Meema HE; Oreopoulos D; Rabinovich S; Fenton S; Wilson DR
Metabolism; 1977 Mar; 26(3):255-65. PubMed ID: 834154
[TBL] [Abstract][Full Text] [Related]
19. Treatment of fracturing renal osteodystrophy by desferrioxamine.
Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
[TBL] [Abstract][Full Text] [Related]
20. Renal osteodystrophy: alpha-Heremans Schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry.
Coen G; Ballanti P; Balducci A; Grandi F; Manni M; Mantella D; Pierantozzi A; Ruggeri M; Sardella D; Sorbo G; Bonucci E
Am J Kidney Dis; 2006 Jul; 48(1):106-13. PubMed ID: 16797392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
